Vascular endothelial growth factor receptor 1 (VEGFR1) tyrosine kinase signaling facilitates granulation tissue formation with recruitment of VEGFR1+ cells from bone marrow

2017 ◽  
Vol 93 (3) ◽  
pp. 372-383 ◽  
Author(s):  
Keiichi Park ◽  
Hideki Amano ◽  
Yoshiya Ito ◽  
Yoshio Mastui ◽  
Mariko Kamata ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Granulation Tissue ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Tissue Formation ◽  
Tyrosine Kinase Signaling ◽  
Granulation Tissue Formation ◽  
Endothelial Growth Factor

Antibody Neutralization of Vascular Endothelial Growth Factor Inhibits Wound Granulation Tissue Formation

2001 ◽  
Vol 96 (2) ◽  
pp. 173-182 ◽  
Author(s):  
Thomas R. Howdieshell ◽  
Dianne Callaway ◽  
Whitney L. Webb ◽  
Michael D. Gaines ◽  
Charles D. Procter ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Granulation Tissue ◽  
Vascular Endothelial ◽  
Tissue Formation ◽  
Antibody Neutralization ◽  
Granulation Tissue Formation ◽  
Endothelial Growth Factor

Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms

2011 ◽  
Vol 64 (3) ◽  
pp. 226-231 ◽  
Author(s):  
Leonardo Boiocchi ◽  
Claudia Vener ◽  
Federica Savi ◽  
Emanuela Bonoldi ◽  
Alessia Moro ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Microvessel Density ◽  
Myeloproliferative Neoplasms ◽  
Philadelphia Chromosome ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Vegf Expression ◽  
Endothelial Growth Factor

AimsThe authors investigated vascular endothelial growth factor receptor 1 (VEGFR-1) protein expression in a series of Philadelphia chromosome-negative myeloproliferative neoplasms (Ph- MPNs) and its correlations with microvessel density (MVD) and vascular endothelial growth factor (VEGF).Methods83 bone marrow biopsies of Ph- MPNs patients, including 27 essential thrombocythaemia (ET), 21 polycythaemia vera (PV) and 35 primary myelofibrosis (PMF), and 10 normal controls (NCs) were investigated by immunohistochemistry.ResultsPatients with PV and PMF showed an increased MVD (PV: 20.1±10.6; PMF: 25.8±6.5) compared with those with ET or NCs (ET: 10.4±4.6; NCs: 7±3.4). VEGFR-1 expression was increased in Ph- MPNs, particularly in PV and PMF (NCs: 0.07±0.03; ET: 0.15±0.09; PV: 0.31±0.2; PMF: 0.31±0.04). VEGF expression parallelled VEGFR-1 and resulted increased in Ph- MPNs (NCs: 0.08±0.04; ET: 0.13±0.06; PV: 0.29±0.2; PMF: 0.31±0.15) and higher in post-polycythaemic myelofibrosis and in the fibrotic stage of PMF than in the non-fibrotic phases of both diseases. VEGFR-1 protein expression correlated with MVD and VEGF expression in Ph- MPNs. VEGFR-1 and VEGF were expressed by the same bone marrow populations: megakaryocytes, macrophages and immature myeloid precursors showed a moderate to strong immunostaining intensity in both Ph- MPNs and NCs. The erythroid precursors were not immunoreactive.ConclusionsVEGFR-1 and VEGF were increased and co-localised in megakaryocytes, macrophages and myeloid precursors of Ph- MPNs. This finding supports the hypothesis of a VEGF/VEGFR-1 autocrine loop in the neoplastic cells of Ph- MPNs.

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document